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Abstract: Oxidative stress is thought to contribute to the aetiology of neurological disorders such as
Parkinson’s disease. Ascorbate (vitamin C) is a potent antioxidant and is associated with neurological
and cognitive function. In this study we assessed the ascorbate status of a cohort of people with
Parkinson’s disease (n = 215), aged 50–90 years, compared with a cohort of age matched healthy
controls (n = 48). The study sample’s cognitive status ranged from normal to mild cognitive
impairment and dementia. There was no difference between the Parkinson’s disease and healthy
control groups with respect to mean ascorbate status, however, a higher proportion of participants
with Parkinson’s disease had hypovitaminosis C (i.e., <23 µmol/L) compared with healthy controls
(20% vs. 8%, respectively). Within the Parkinson’s disease group, Montreal Cognitive Assessment
(MoCA) scores correlated positively with ascorbate concentrations, with higher ascorbate status
associated with better cognitive function (r = 0.14, p = 0.045). Participants with hypovitaminosis
C had significantly lower MoCA scores relative to participants with ascorbate concentrations
>23 µmol/L (p = 0.014). Ascorbate concentrations were significantly lower in the cognitively impaired
subgroup compared with the normal cognition subgroup in the Parkinson’s disease cohort (p = 0.03).
In contrast, urate showed an inverse correlation with cognitive function (r = −0.19, p = 0.007),
with higher urate concentrations observed in the cognitively impaired subgroup compared with the
normal cognition subgroup (p = 0.015). There was an inverse association between ascorbate status
and urate concentrations (r = −0.15, p = 0.017). Plasma protein carbonyls, a measure of systemic
oxidative stress, were not significantly different between the Parkinson’s disease cohort and healthy
controls, and there was no association with cognitive function (r = 0.09, p = 0.19) or with ascorbate
status (r = −0.05, p = 0.45). Overall, our study showed ascorbate status was positively associated
with cognitive function in Parkinson’s disease, suggesting that longitudinal studies investigating the
temporal sequence of cognitive decline and ascorbate status are warranted.
Keywords: vitamin C; ascorbate; ascorbic acid; Parkinson’s disease; cognitive impairment; MoCA;
antioxidant; oxidative stress
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1. Introduction
Parkinson’s disease is the most common age-related neurodegenerative disorder after Alzheimer’s
disease [1]. More than 10 million people currently live with Parkinson’s disease, and prevalence is
expected to double in 20 years [2,3]. Once diagnosed, substantial loss of dopaminergic neurons in
the substantia nigra pars compacta and depleted dopamine availability in the striatum is already
evident [4]. Diagnosis is based on typical motor symptoms, especially bradykinesia, muscular rigidity,
and tremor at rest [5]. No medications yet exist that can slow the progression of Parkinson’s disease [4].
Interventions treat symptoms only, and are primarily for improving health-related quality of life [6].
The quality of life of people with Parkinson’s disease is also impacted by many nonmotor
features, both before and after diagnosis. Nonmotor changes include sleep, autonomic, olfactory, pain,
and psychiatric symptoms [6]. People with Parkinson’s disease also experience cognitive decline,
often the most disabling nonmotor feature [7]. The cognitive decline frequently becomes severe enough
to significantly affect every-day cognition, leading to a dementia diagnosis, institutional admission,
and reduced lifespan [4,6].
Meta-analysis has indicated that people with Parkinson’s disease dementia tend to have lower
serum urate concentrations than controls, and there was a positive correlation between serum urate
and cognitive function in people with Parkinsons’ disease dementia [8]. Urate, a metabolite of
purine nucleotides, is an antioxidant in blood and brain tissue that exerts neuroprotective effects by
scavenging reactive oxygen species [9,10]. Although urate has been associated with cognitive function
in older people, the data is somewhat conflicting and may depend on the aetiology of the dementia,
with protective effects being observed in Parkinson’s dementia and Alzheimer’s disease, but not in
vascular dementia [11].
Plasma ascorbate concentrations have also been associated with cognition in the general population,
with cognitively impaired groups having lower mean ascorbate status than cognitively intact groups [12].
Ascorbate (vitamin C) is a potent antioxidant obtained through the diet. In the brain, ascorbate
is maintained at high concentrations relative to other organs [13], and low levels are linked to
neurodegenerative diseases [14,15]. Previous research has indicated that patients with Parkinson’s
disease have significantly lower concentrations of plasma ascorbate and higher concentrations of
oxidative stress markers compared to healthy controls [16,17]. Furthermore, decreased concentrations
of leukocyte ascorbate is correlated with disease severity assessed by Hoehn–Yahr stage in Parkinsons’
disease patients [18].
The current study examined the association between plasma ascorbate and cognitive function in
participants with Parkinson’s disease and in healthy controls using the Montreal Cognitive Assessment
(MoCA). To capture the spectrum of cognition in Parkinson’s disease, we included patients who
had been classified as having either normal cognition (PD-N), mild cognitive impairment (PD-MCI),
or dementia (PD-D). Ascorbate has numerous biosynthetic and regulatory functions in addition to
its well-known antioxidant activities, so we assessed both antioxidants and oxidatively damaged
molecules. For the latter, we examined protein carbonyls, as a stable marker of systemic oxidative stress.
2. Materials and Methods
2.1. Parameters of the Study Sample
A cohort of people with Parkinson’s disease (n = 215) was recruited by the New Zealand Brain
Research Institute (NZBRI) and blood samples were collected between August 2016 and February
2019. They were diagnosed using the Movement Disorder Society Clinical Diagnostic Criteria for
Parkinson’s disease (MSD-PD) [19]. For comparison, blood samples were collected from a cohort of
healthy individuals (n = 48) matched for age and gender.
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2.2. Neuropsychological Testing
Comprehensive assessment meeting the Movement Disorders Society (MDS) Task Force level II
criteria classified Parkinson’s disease patients as either PD-N, PD-MCI, or PD-D using neuropsychological
test spanning five cognitive domains (executive function; attention, working memory and processing
speed; learning and memory; visuospatial/visuoperceptual function; language) [20,21]. PD-MCI cases did
not have significantly impaired functional activities of daily living and scored ≥1.5 SD below normative
data on two tests in at least one of the five cognitive domains [22]. PD-D cases had poor cognitive
performance (i.e., 2 SD below normative data in at least two of the five cognitive domains) associated
with significant impairment in everyday functional activities, not attributed to motor impairments [20].
2.3. Montreal Cognitive Assessment (MoCA)
The majority of participants (n = 260) from both the Parkinson’s disease and control groups
were evaluated with the MoCA, a global mental status test [23,24]. MoCA scores range from 0 to
30. MoCA scores in PD correspond to cognitive status as determined by a full neuropsychological
evaluation (26–30: normal cognitive status, 21–25: mild cognitive impairment, <21: dementia).
2.4. Hoehn and Yahr Scale
Most of the Parkinson’s disease cohort (n = 187) were evaluated with the modified Hoehn and
Yahr scale at the time of giving their blood sample [25]. This evaluation stages motor symptoms on
an eight-point scale from stage 0, no signs of disease, to stage 5, individual is wheelchair bound or
bedridden unless assisted.
2.5. Unified Parkinson’s Disease Rating Scale (UPDRS)
Motor functions were also assessed in the majority of the Parkinson’s disease group (n = 187)
using part III of the Movement Disorder Society revision of the Unified Parkinson’s Disease Rating
Scale (MDS-UPDRS) [26]. This instrument uses 18 items, rating symptoms such as tremor, speech,
facial expression, gait, and rigidity on a five-point scale from 0 (normal function) to 4 (severe dysfunction).
In Part III, scores >32 indicate moderate symptom severity and >58 indicates severe symptom severity
(maximum score = 132).
2.6. Blood Sample Collection and Processing
Nonfasting blood samples were collected by venipuncture into lithium heparin anticoagulant
vacutainers and placed immediately on ice for biomarker stability [27]. Samples were centrifuged at
4000× g for 10 min at 4 ◦C, and the separated plasma was stored at −80 ◦C.
2.7. Ascorbate and Urate Measurement by HPLC
The total ascorbate and urate content of plasma was analysed using reverse-phase
high-performance liquid chromatography (HPLC) with electrochemical detection, as previously
described [28]. Prior to HPLC analysis, the samples were treated with an equal volume of
ice-cold 0.54 M perchloric acid (PCA) solution containing 100 µmol/L of the metal chelator
diethylenetriaminepentaacetic acid (DTPA) to precipitate proteins and stabilise the ascorbate. To recover
any ascorbate that had become oxidised during processing and/or storage, the PCA-supernatant was
treated with 10% v/v tris(2carboxyethyl)phosphine (TCEP; 350 mmol/L) for 3 h at 4 ◦C. Samples
were separated on a Synergi 4 µ Hydro-RP 80A 150 × 4.6 mm column (Phenomenex NZ Ltd.,
Auckland, New Zealand) using a Dionex Ultimate 3000 HPLC unit with a refrigerated autosampler
and an ESA Coulochem II electrochemical detector at +200 mV electrode potential and 20 µA
sensitivity (Thermo Fisher Scientific, Auckland, New Zealand). The mobile phase comprised 80 mM
sodium acetate buffer, pH 4.8, containing DTPA (0.54 mmol/L) and freshly added paired-ion reagent
n-octylamine (1µmol/L), delivered at a flow rate of 1.2 mL/min. A standard curve of sodium-L-ascorbate
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(1.25–20 µmol/L) and uric acid (1.25–20 µmol/L), standardised spectrophotometrically, were freshly
prepared for each HPLC run in 77 mmol/L perchloric acid containing 100 µmol/L DTPA.
2.8. Protein Carbonyl Measurement by ELISA
Plasma protein carbonyl concentrations were measured using an enzyme-linked immunosorbent
assay (ELISA) as previously described [29]. Samples and standards were derivatised with 0.1 mM
dinitrophenylhydrazine (DNP) in 6 M guanidine hydrochloride for 45 min while at room temperature.
Each standard and sample was then diluted in PBS, and 200 µL aliquots were added into the ELISA
plate wells in triplicate and incubated at 4 ◦C overnight. The ELISA plate was washed three times with
PBS and blocked with PBS containing 0.1% (v/v) Tween 20 at room temperature for 30 min. The plate
was then washed again and the bound protein was probed with a biotinylated anti-DNP antibody at
1:1000 in PBS containing 0.1% (v/v) Tween 20 for 1 h at 37 ◦C. The plate was rewashed, and probed with
streptavidin-linked horseradish peroxidase at a 1:1000 dilution in PBS containing 0.1% (v/v) Tween
20 and incubated for 1 h at room temperature. The plate was washed again and Chromatin reagent
added to each well. The colour development process was stopped after approximately 5 min by adding
2.5 M sulfuric acid. Absorbance was measured at 450 nm on a Thermo Scientific Multiskan GO plate
reader using Thermo Scientific SkanIt 5.0 software (Thermo Fisher Scientific, Auckland, New Zealand).
Protein carbonyl concentrations were calculated using a standard curve plotted using the pmol/mg
protein carbonyl concentration of the standards and their absorbance values.
2.9. Statistical Analyses
Pearson’s linear correlation analyses were used to express the relationship between continuous
variables and unpaired t-tests were used to compare groups. Categorical data were examined
using Chi-squared tests with 2 × 2 contingency tables. Statistical analyses were conducted using
Microsoft Excel data analysis add-in (Microsoft, Auckland, NZ) and GraphPad Prism version 8.0
(GraphPad Software, San Diego, CA, USA). Statistical significance was set at p < 0.05.
3. Results
3.1. Participant Characteristics
In the Parkinson’s disease group (n = 215), 70% were male and the mean age was 73 ± 7 years
(with a range of 51–89 years; Table 1). Most participants self-identified as NZ European (n = 204, 95%).
There were 95 (44%) PD-N, 84 (39%) PD-MCI, and 35 (16%) PD-D; all healthy controls had normal
cognition for their age. Mean MoCA scores in the Parkinson’s disease group were significantly lower
than those of the healthy controls (24 ± 5 vs. 27 ± 3, respectively, p < 0.0001). Hoehn and Yahr stage
of 2.6 ± 0.6 indicated mild bilateral involvement on the pull test and was comparable across the PD
subgroups. The mean UPDRS part III score of 40 ± 14 indicated that most had moderate Parkinson’s
disease motor symptoms when on antiparkinsonian medication.
Table 1. Participant characteristics.









Age, years 1 72 ± 7 73 ± 7 70 ± 7 72 ± 7 76 ± 5
Male, n (%) 29 (60) 150 (70) 59 (62) 62 (74) 29 (83)
Cognitive status, n (%) 2
Normal 45 (94) 95 (44) - - -
MCI 2 (4) 84 (39) - - -
Dementia 1 (2) 35 (16) - - -
MoCA score 27 ± 3 24 ± 5 27 ± 2 23 ± 3 17 ± 5
Hoehn and Yahr scale - 2.6 ± 0.6 2.4 ± 0.5 2.7 ± 0.7 3.0 ± 0.7
UPDRS part III score - 40 ± 14 34 ± 13 45 ± 13 49 ± 13
1 Data are presented as mean ± SD, unless otherwise specified. 2 Cognitive status was not determined for one
participant in the PD group. PD, Parkinson’s disease; N, normal; MCI, mild cognitive impairment; D, dementia;
MoCA, Montreal Cognitive Assessment; UPDRS, Unified Parkinson’s Disease Rating Score.
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3.2. Ascorbate Status of the Study Population
The mean plasma ascorbate concentration for the total cohort was 47 ± 22 µmol/L (n = 262). Females
had nonsignificantly higher levels than males (50 ± 23 µmol/L vs. 45 ± 22 µmol/L; p = 0.07). There was
no difference in mean levels between the Parkinson’s disease and control groups (47 ± 23 µmol/L vs.
48 ± 20 µmol/L; p = 0.74; Figure 1A). Participants were assigned to five categories based on their
ascorbate status: saturating (>70 µmol/L), adequate (>50 µmol/L), lower than recommended (<50 µmol/L),
hypovitaminosis C (<23 µmol/L), and deficient (<11 µmol/L) [30]. There was a significantly higher
proportion of hypovitaminosis C in the Parkinson’s disease group relative to the healthy controls (20% vs.
8%, p = 0.048; Figure 1B).
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adequate (>50 μmol/L), lower than recommended (<50 μmol/L), hypovitaminosis C (<23 μmol/L), and 
deficient (<11 μmol/L) plasma ascorbate concentrations [30]. Categories are shown as percentages. 
The PD group had a significantly higher proportion of hypovitaminosis C (p = 0.048). 
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Figure 1. Ascorbate status of the study opulation. (A) Box plot show medians i l rbate
concentrations in the Parkinson’s disease (PD) group (n = 214) and control group (n = 48). Boundaries are
set at the 25th and 75th percentiles, whiskers at 5th and 95th percentiles, outliers are indicated by
symbols. Mean plasma ascorbate concentrations were not significantly different between the two
groups (p = 0.74). (B) Proportion of participants in different ascorbate categories. Individuals within
the Parkinson’s disease (PD) and control groups were classified as having saturating (>70 µmol/L),
adequate (>50 µmol/L), lower than recommended (<50 µmol/L), hypovitaminosis C (<23 µmol/L),
and deficient (<11 µmol/L) plasma ascorbate concentrations [30]. Categories are shown as percentages.
The PD group had a significantly higher proportion of hypovitaminosis C (p = 0.048).
3.3. Ascorbate Status Relative to Cognitive Function and Clinical Parameters
In the Parkinson’s disease group (n = 212), MoCA scores showed a weak positive correlation
with plasma a corbate concentrations (r = 0.14, p = 0.045; Figure 2A). Thus, a high r ascorbate
status was associated with a better cognitive score. A comparable correl tion was observed with
the healthy controls (r = 0.29, p = 0.048). When the MoCA data was analysed relative to ascorbate
status, participants with hypovitaminosis C (i.e., <23 µmol/L) had significantly lower MoCA scores
relative to participants with ascorbate concentrations >23 µmol/L (21.9 ± 6.0 vs. 23.9 ± 4.4, p = 0.014).
The mean ascorbate concentration in the cognitively impaired group (PD-MCI and PD-D combined;
43 ± 23 µmol/L, n = 118) was significantly lower than that of the PD-N group (50 ± 23 µmol/L, n = 95,
p = 0.03; Figure 2B). There was no evidence of a correlation between ascorbate status and the Hoehn
and Yahr scale (r = −0.03, p = 0.64), or between ascorbate status and UPDRS Part III scores (r = −0.06,
p = 0.42) in the Parkinson’s disease group.
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Cognitive Assessment) scores in the Parkinson’s disease group (n = 212) sho ed a significant positive
correlation with ascorbate status (r = 0.14, p = 0.045). (B) Plasma ascorbate concentrations in individuals
with Parkinson’s disease as per cognitive status subgroups: normal (PD-N, n = 95), mild cognitive
impairment (PD-MCI, n = 84), and dementia (PD-D, n = 34); the cognitively impaired group (PD-MCI
and PD-D combined, n = 118) was significantly lower than the PD-N group (p = 0.03). Box plots
show medians with boundaries set at 25th and 75th percentiles, whiskers at 5th and 95th percentiles,
outliers are indicated by symbols.
3.4. Urate Concentrations Relative to Cognitive Function and Clinical Parameters
Plasma urate concentrations were not significantly different between the Parkinson’s disease
and control groups (198 ± 36 µmol/L vs. 207 ± 31 µmol/L, respectively, p = 0.08). None of the
participants had hyperuricemia, defined as plasma concentrations >360 µmol/L. MoCA scores analysed
against plasma urate concentrations in the Parkinson’s diseas group (n = 212) showed a small inverse
association (r = −0.19, p = 0.007; Figure 3A), i.e., higher urate was associated with worse cognitive
scores. In contrast, no correlation was observed between MoCA scores and urate concentrations in
the healthy cohort (r = 0.11, p = 0.4). The urate values in the cognitively impaired group (PD-MCI
and PD-D combined; 203 ± 37 µmol/L, n = 118) were significantly higher than the PD-N group
(191 ± 35 µmol/L, n = 95, p = 0.015; Figure 3B). In addition, there was a small but positive correlation
between UPDRS part III scores and plasma urate concentrations (r = 0.18, p = 0.02), suggesting that
higher plasma urate is associated with worse motor skill scores. The correlation between plasma urate
concentrations and Hoehn and Yahr scores did not reach significance (r = 0.14, p = 0.06). There was a
weak inverse correlation between ascorbate and urate concentrations in the Parkinson’s disease group
(r = −0.15, p = 0.017), with higher plasma ascorbate concentrations associated with lower plasma urate
concentrations (Figure 3C).
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cognitively impaired group (PD-MCI and PD-D combined; 179 ± 30 pmol/mg protein, n = 118; p = 
0.007; Figure 4). However, MoCA scores analysed against plasma protein carbonyl concentrations in 
the Parkinson’s disease group (n = 212) showed no evidence of association (r = 0.09, p = 0.16). This 
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Figure 3. Plasma urate concentrations relative to cognitive function and plasma ascorbate status.
(A) Montreal Cognitive Assessment (MoCA) scores in the Parkinson’s disease group (n = 212) showed
a significant inverse correlation with urate status (r = −0.19, p = 0.007). (B) Plasma urate concentrations
in individuals with Parkinson’s disease as per cognitive status subgroups: normal (PD-N, n = 95),
mild cognitive impairment (PD-MCI, n = 84), and dementia (PD-D, n = 34). The cognitively impaired
group (PD-MCI and PD-D combined, n = 118) was significantly higher than the PD-N group (p = 0.015).
Box plots show medians with boundaries set at 25th and 75th percentiles, whiskers at 5th and 95th
percentiles, outliers are indicated by symbols. (C) Plasma urate concentrations in the Parkinson’s disease
group (n = 212) show a weak inverse correlation with plasma ascorbate concentrations (r = −0.15,
p = 0.017).
3.5. Protein Carbonyl Concentrations Relative to Cognitive Function and Clinical Parameters
There was no significant difference in protein carbonyl concentrations between the Parkinson’s
disease and control groups (190 ± 7 vs. 191 ± 39 pmol/mg protein; p = 0.8). Two participants in
the Parkinson’s disease group had protein carbonyl concentrations of 969 and 603 pmol/mg protein.
The reason for these high concentrations is not known, but did not appear to relate to cognitive
function as both were in the PD-N subgroup. Even with exclusion of these two outliers, the protein
carbonyl values in the PD-N group (191 ± 36 pmol/mg protein, n = 96) were significantly higher than
the cognitively impaired group (PD-MCI and PD-D combined; 179 ± 30 pmol/mg protein, n = 118;
p = 0.007; Figure 4). However, MoCA scores analysed against plasma protein carbonyl concentrations
in the Parkinson’s disease group (n = 212) showed no evidence of association (r = 0.09, p = 0.16).
This was true also for the healthy control group (r = 0.07, p = 0.65). Additionally, there was no
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significant correlation between plasma protein carbonyl concentrations and Hoehn and Yahr scores
(r = −0.12, p = 0.09) or UPDRS part III scores (r = −0.13, p = 0.06) in the Parkinson’s disease group.
There was no significant correlation between protein carbonyl concentrations and plasma ascorbate
status (r = −0.05, p = 0.45) or urate concentrations (r = −0.06, p = 0.4).
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4. Discussion
In this study, we observed that people with Parkinson’s disease had similar mean plasma ascorbate
status to healthy age-matched controls, values which were comparable to a previously reported study
in Spain [31]. Although other studies (in India and Brazil) have shown lower ascorbate concentrations
in people with Parkinson’s disease compared to healthy controls [16,17], based on the low control
values and the less than ideal analytical methodology used, it is possible that these low values were
due to artifactual ex vivo oxidation [27]. Alternatively, individuals in low-middle income countries
tend to have lower vitamin C status, and thus may be more prone to developing hypovitaminosis C
during various disease states [32,33]. Of note, the Parkinson’s disease group in our study had a higher
prevalence of hypovitaminosis C, where the subclinical symptoms of vitamin C deficiency start to
become apparent [34].
We observed lower ascorbate status associated with cognitive decline in the Parkinson’s disease
group, in line with a previous report which indicated decreasing vitamin C status with severity of
the disease [18]. Participants with hypovitaminosis C, in particular, had significantly lower mean
MoCA scores than those with ascorbate status >23 µmol/L. Previous studies have reported lower
ascorbate status in people with cognitive impairment, e.g., Alzheimer’s disease [12]. There are, however,
a paucity of studies examining the role of ascorbate in the cognitive decline related to Parkinson’s
disease progression. We also observed a positive association of ascorbate status with cognitive function
in the healthy control group, which has been observed previously in middle-aged people in the general
population [35]. Therefore, the association of ascorbate with cognitive function is not specific to people
with neurological disease, but is a more generalisable phenomenon.
There are a number of activities of vitamin C that are believed to contribute to brain function [36].
For example, ascorbate acts as an antioxidant in the brain, which, due to its high metabolic
rate, is particularly exposed to oxidative stress. Ascorbate also plays a role in the synthesis of
dopamine [14,37]. Additionally, ascorbate has been shown to have a role in the epigenetic mechanisms
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of gene expression [38]. Abnormalities in the concentrations of the epigenetic marks 5-methyl
cytosine and 5-hydroxymethyl cytosine in the brain have been associated with the development of
neurodegenerative diseases, including Parkinson’s disease [39,40]. More recently, ascorbate treatment
of human induced pluripotent stem cells was shown to elevate gene expressions of the epigenetic
enzymes TET2, TET3, and ascorbate transporters, and promote neuronal maturation, synaptic activity,
and dopamine release [41].
In our study, urate concentrations were nonsignificantly lower in the Parkinson’s disease group
compared with the control group. However, we did observe a small inverse correlation between
urate concentrations and MoCA scores in the Parkinson’s disease group, with higher plasma urate
concentrations associated with worse cognitive scores. This is consistent with longitudinal studies that
reported elevated baseline serum urate concentrations were associated with faster cognitive decline
over time [42,43]. There are, however, conflicting reports in the literature around the association of
urate with cognitive function. A 2016 systematic review of ≈16,000 participants over 46 papers found
no clear association between serum urate levels and cognition [44], although the studies analysed
included patients with Alzheimer’s disease, Parkinson’s disease, MCI, and dementia-free people,
making interpretation of the results challenging [45]. Additionally, findings may be complicated by
the presence of comorbidities such as kidney and cardiovascular disease [46,47].
We observed a weak inverse correlation between plasma ascorbate and urate concentrations,
with higher ascorbate associated with lower urate concentrations, as has been observed in other
studies [48,49]. The uricosuric effects of ascorbate are thought to be responsible for the reduction in
urate levels [50], but it is also thought that ascorbate may inhibit uric acid synthesis [51]. Alternatively,
higher ascorbate may indicate a healthier diet, i.e., one with more fresh fruit and vegetables [52],
versus a purine-rich diet that can contribute to higher urate concentrations.
As ascorbate and urate had opposite associations with cognitive function, despite both being
considered antioxidants, this indicates that other non-antioxidant functions of ascorbate may be playing
a role in cognitive function. The lack of an association between MoCA scores and protein carbonyls,
a stable marker of oxidative stress, and between protein carbonyls and ascorbate in our study lends
confirmation to this premise. Protein carbonyls are a general marker of oxidative stress as they can be
formed by a variety of reactive oxygen species and via a number of different reaction pathways [53].
Although protein carbonyls have been negatively associated with MoCA scores in patients with
Alzheimer’s disease [54], relatively few studies have measured protein oxidation in people with
Parkinson’s disease and these have yielded contradictory results [55,56]. Although elevated lipid
oxidation markers have been observed in Parkinson’s disease [16,17], there is as yet no clear link
between oxidative stress and cognitive function in Parkinson’s disease. However, assessing peripheral
biomarkers of oxidative stress may not accurately reflect processes occurring in the brain as Parkinson’s
neuropathology is restricted to a relatively small volume of the brain [57].
A limitation of this observational study is the lack of certainty around direction of causality.
Decreased ascorbate levels may lead to worse cognitive status, however, the opposite is also a
possibility in that people with reduced cognitive capacity do not eat as well, which can result
in nutritional deficiencies. Additionally, plasma ascorbate may simply be a marker of a healthy
diet [52], without any direct activity itself on cognitive function. Nevertheless, the vitamin does have
biological plausibility with a number of activities that conceivably contribute to brain function [36].
Another potential limitation of the study is the nonfasting nature of the collected blood samples.
However, the vitamin C status of people in the hypovitaminosis range is less susceptible to fluctuations
as a result of recent dietary intake [58]. Compared with plasma, leukocyte ascorbate concentrations
are considered a more stable measure, less affected by transient dietary changes [59]. Interestingly,
lymphocyte ascorbate concentrations have been reported to be lower in patients with severe Parkinson’s
disease, when compared to patients at less severe stages, suggesting that lymphocyte ascorbate
concentrations could be a potential marker for progression of the disease [18].
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5. Conclusions
Our study showed a positive association of ascorbate status with cognitive function in people with
Parkinson’s disease. Due to the uncertainty around the direction of causality, it would be worthwhile
to conduct a longitudinal study to probe the temporal sequence of cognitive decline and ascorbate
status. This would indicate if further studies investigating the role of ascorbate supplementation in
cognitive decline in individuals with Parkinson’s disease are warranted.
Author Contributions: Conceptualisation, A.C.C., M.M., T.P.; investigation, E.S.S., T.P., G.V., T.H.; supervision;
A.C.C., E.S.S.; writing—original draft preparation, E.S.S., A.C.C.; writing—review and editing, T.P., G.V., T.H.,
M.M., T.A., J.D.-A. All authors have read and agreed to the published version of the manuscript.
Funding: This study was partly funded by the Health Research Council of New Zealand (14/440) and Lottery
Health Research (LHR-2018-72382).
Acknowledgments: A.C.C. is the recipient of the Sir Charles Hercus Health Research Fellowship from the Health
Research Council of New Zealand. We thank the Cancer Society Tissue Bank for blood sample processing
and storage.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Ping, L.; Duong, D.M.; Yin, L.; Gearing, M.; Lah, J.J.; Levey, A.I.; Seyfried, N.T. Global quantitative analysis
of the human brain proteome in Alzheimer’s and Parkinson’s Disease. Sci. Data 2018, 5, 180036. [CrossRef]
[PubMed]
2. Ball, N.; Teo, W.-P.; Chandra, S.; Chapman, J. Parkinson’s Disease and the Environment. Front. Neurol. 2019,
10, 218. [CrossRef] [PubMed]
3. Dorsey, E.R.; Sherer, T.; Okun, M.S.; Bloemd, B.R. The emerging evidence of the Parkinson pandemic.
J. Parkinsons Dis. 2018, 8, S3–S8. [CrossRef] [PubMed]
4. Kalia, L.V.; Lang, A.E. Parkinson’s disease. Lancet 2015, 386, 896–912. [CrossRef]
5. Erro, R.; Stamelou, M. The motor syndrome of Parkinson’s Disease. In International Review of Neurobiology;
Academic Press Inc.: Cambridge, MA, USA, 2017; pp. 25–32.
6. Williams-Gray, C.H.; Worth, P.F. Parkinson’s Disease, Medicine (United Kingdom); Elsevier Ltd.: Amsterdam,
The Netherlands, 2016; Volume 44, pp. 542–546.
7. Chen-Plotkin, A.S.; Hu, W.T.; Siderowf, A.; Weintraub, D.; Goldmann Gross, R.; Hurtig, H.I.; Xie, S.X.;
Arnold, S.E.; Grossman, M.; Clark, C.M.; et al. Plasma epidermal growth factor levels predict cognitive
decline in Parkinson disease. Ann. Neurol. 2011, 69, 655–663. [CrossRef]
8. Wen, M.; Zhou, B.; Chen, Y.H.; Ma, Z.L.; Gou, Y.; Zhang, C.L.; Yu, W.; Jiao, L. Serum uric acid levels in
patients with Parkinson’s disease: A meta-analysis. PLoS ONE 2017, 12, e0173731. [CrossRef]
9. Glantzounis, G.; Tsimoyiannis, E.; Kappas, A.; Galaris, D. Uric Acid and Oxidative Stress. Curr. Pharm. Des.
2005, 11, 4145–4151. [CrossRef]
10. Schlesinger, I.; Schlesinger, N. Uric acid in Parkinson’s disease. Mov. Disord. 2008, 23, 1653–1657. [CrossRef]
11. Tana, C.; Ticinesi, A.; Prati, B.; Nouvenne, A.; Meschi, T. Uric acid and cognitive function in older individuals.
Nutrients 2018, 10, 975. [CrossRef]
12. Travica, N.; Ried, K.; Sali, A.; Scholey, A.; Hudson, I.; Pipingas, A. Vitamin c status and cognitive function:
A systematic review. Nutrients 2017, 9, 960. [CrossRef]
13. Harrison, F.E.; May, J.M. Vitamin C function in the brain: Vital role of the ascorbate transporter SVCT2.
Free Radic. Biol. Med. 2009, 46, 719–730. [CrossRef] [PubMed]
14. Kocot, J.; Luchowska-Kocot, D.; Kiełczykowska, M.; Musik, I.; Kurzepa, J. Does vitamin C influence
neurodegenerative diseases and psychiatric disorders? Nutrients 2017, 9, 659. [CrossRef] [PubMed]
15. Moretti, M.; Fraga, D.B.; Rodrigues, A.L.S. Preventive and therapeutic potential of ascorbic acid in
neurodegenerative diseases. CNS Neurosci. Ther. 2017, 23, 921–929. [CrossRef] [PubMed]
16. Medeiros, M.S.; Schumacher-Schuh, A.; Cardoso, A.M.; Bochi, G.V.; Baldissarelli, J.; Kegler, A.; Santana, D.;
Chaves, C.M.M.B.S.; Schetinger, M.R.C.; Moresco, R.N.; et al. Iron and oxidative stress in Parkinson’s disease:
An observational study of injury biomarkers. PLoS ONE 2016, 11, e0146129. [CrossRef] [PubMed]
Antioxidants 2020, 9, 906 11 of 13
17. Sudha, K.; Rao, A.V.; Rao, S.; Rao, A. Free radical toxicity and antioxidants in Parkinson’s disease. Neurol. India
2003, 51, 60–62. [PubMed]
18. Ide, K.; Yamada, H.; Umegaki, K.; Mizuno, K.; Kawakami, N.; Hagiwara, Y.; Matsumoto, M.; Yoshida, H.;
Kim, K.; Shiosaki, E.; et al. Lymphocyte vitamin C levels as potential biomarker for progression of Parkinson’s
disease. Nutrition 2015, 31, 406–408. [CrossRef] [PubMed]
19. Hughes, A.J.; Daniel, S.E.; Kilford, L.; Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson’s
disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55, 181–184.
[CrossRef]
20. Wood, K.L.; Myall, D.J.; Livingston, L.; Melzer, T.R.; Pitcher, T.L.; MacAskill, M.R.; Geurtsen, G.J.;
Anderson, T.J.; Dalrymple-Alford, J.C. Different PD-MCI criteria and risk of dementia in Parkinson’s
disease: 4-year longitudinal study. npj Park Dis. 2016, 2, 1–8. [CrossRef]
21. Litvan, I.; Goldman, J.G.; Tröster, A.I.; Schmand, B.A.; Weintraub, D.; Petersen, R.C.; Mollenhauer, B.;
Adler, C.H.; Marder, K.; Williams-Gray, C.H.; et al. Diagnostic criteria for mild cognitive impairment in
Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 2012, 27, 349–356.
[CrossRef]
22. Emre, M.; Aarsland, D.; Brown, R.; Burn, D.J.; Duyckaerts, C.; Mizuno, Y.; Broe, G.A.; Cummings, J.;
Dickson, D.W.; Gauthier, S.; et al. Clinical diagnostic criteria for dementia associated with Parkinson’s
disease. Mov. Disord. 2007, 22, 1689–1707. [CrossRef]
23. Nasreddine, Z.S.; Phillips, N.A.; Bédirian, V.; Charbonneau, S.; Whitehead, V.; Collin, I.; Cummings, J.L.;
Chertkow, H. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive
impairment. J. Am. Geriatr. Soc. 2005, 53, 695–699. [CrossRef] [PubMed]
24. Dalrymple-Alford, J.C.; MacAskill, M.R.; Nakas, C.T.; Livingston, L.; Graham, C.; Crucian, G.P.; Melzer, T.R.;
Kirwan, J.; Keenan, R.; Wells, S.; et al. The MoCA: Well-suited screen for cognitive impairment in Parkinson
disease. Neurology 2010, 75, 1717–1725. [CrossRef] [PubMed]
25. Goetz, C.G.; Poewe, W.; Rascol, O.; Sampaio, C.; Stebbins, G.T.; Counsell, C.; Giladi, N.; Holloway, R.G.;
Moore, C.G.; Wenning, G.K.; et al. Movement Disorder Society Task Force report on the Hoehn and Yahr
staging scale: Status and recommendations. Mov. Disord. 2004, 19, 1020–1028. [CrossRef] [PubMed]
26. Martinez-Martin, P.; Chaudhuri, K.R.; Rojo-Abuin, J.M.; Rodriguez-Blazquez, C.; Alvarez-Sanchez, M.;
Arakaki, T.; Bergareche-Yarza, A.; Chade, A.; Garretto, N.; Gershanik, O.; et al. Assessing the non-motor
symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale. Eur. J. Neurol. 2015, 22, 37–43. [CrossRef]
[PubMed]
27. Pullar, J.M.; Bayer, S.; Carr, A.C. Appropriate handling, processing and analysis of blood samples is essential
to avoid oxidation of vitamin C to dehydroascorbic acid. Antioxidants 2018, 7, 29. [CrossRef]
28. Carr, A.C.; Pullar, J.M.; Moran, S.; Vissers, M.C.M. Bioavailability of vitamin C from kiwifruit in non-smoking
males: Determination of “healthy” and “optimal” intakes. J. Nutr. Sci. 2012, 1, 1–9. [CrossRef]
29. Buss, H.; Chan, T.P.; Sluis, K.B.; Domigan, N.M.; Winterbourn, C.C. Protein carbonyl measurement by a
sensitive ELISA method. Free Radic. Biol. Med. 1997, 23, 361–366. [CrossRef]
30. Wilson, R.; Willis, J.; Gearry, R.; Skidmore, P.; Fleming, E.; Frampton, C.; Carr, A. Inadequate vitamin C status
in prediabetes and type 2 diabetes mellitus: Associations with glycaemic control, obesity, and smoking.
Nutrients 2017, 9, 997. [CrossRef]
31. Férnandez-Calle, P.; Jiménez-Jiménez, F.J.; Molina, J.; Cabrera-Valdivia, F.; Vázquez, A.; Urra, D.G.; Bermejo, F.;
Matallana, M.C.; Codoceo, R. Serum levels of ascorbic acid (vitamin C) in patients with Parkinson’s disease.
J. Neurol. Sci. 1993, 118, 25–28. [CrossRef]
32. Rowe, S.; Carr, A.C. Global Vitamin C Status and Prevalence of Deficiency: A Cause for Concern? Nutrients
2020, 12, 2008. [CrossRef]
33. Carr, A.C.; Rowe, S. Factors affecting vitamin C status and prevalence of deficiency: A global health
perspective. Nutrients 2020, 12, 1963. [CrossRef]
34. Levine, M.; Conry-Cantilena, C.; Wang, Y.; Welch, R.W.; Washko, P.W.; Dhariwal, K.R.; Park, J.B.; Lazarev, A.;
Graumlich, J.F.; King, J.; et al. Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended
dietary allowance. Proc. Natl. Acad. Sci. USA 1996, 93, 3704–3709. [CrossRef] [PubMed]
35. Pearson, J.F.; Pullar, J.M.; Wilson, R.; Spittlehouse, J.K.; Vissers, M.C.M.; Skidmore, P.M.L.; Willis, J.;
Cameron, V.A.; Carr, A.C. Vitamin C status correlates with markers of metabolic and cognitive health in
50-year-olds: Findings of the CHALICE cohort study. Nutrients 2017, 9, 831. [CrossRef] [PubMed]
Antioxidants 2020, 9, 906 12 of 13
36. May, J.M. Vitamin C transport and its role in the central nervous system. Subcell Biochem. 2012, 56, 85–103.
[PubMed]
37. Meredith, M.E.; May, J.M. Regulation of embryonic neurotransmitter and tyrosine hydroxylase protein levels
by ascorbic acid. Brain Res. 2013, 1539, 7–14. [CrossRef]
38. Young, J.I.; Züchner, S.; Wang, G. Regulation of the Epigenome by Vitamin C. Ann. Rev. Nutr. 2015, 35,
545–564. [CrossRef] [PubMed]
39. Kwon, M.J.; Kim, S.; Han, M.H.; Lee, S.B. Epigenetic changes in neurodegenerative diseases. Mol. Cells 2016,
39, 783–789. [CrossRef]
40. Kaut, O.; Kuchelmeister, K.; Moehl, C.; Wüllner, U. 5-methylcytosine and 5-hydroxymethylcytosine in brains
of patients with multiple system atrophy and patients with Parkinson’s disease. J. Chem. Neuroanat. 2019, 96,
41–48. [CrossRef]
41. Xiang, L.; Huang, G.; Shu, W.; Gong, C.; Cao, N.; Chen, R.; Li, J.; Lu, H.; Jiang, G. Role of Chromatin
Remodeling Genes and TETs in the Development of Human Midbrain Dopaminergic Neurons. Stem Cell
Rev. Rep. 2020. [CrossRef]
42. Beydoun, M.A.; Canas, J.A.; Dore, G.A.; Beydoun, H.A.; Rostant, O.S.; Fanelli-Kuczmarski, M.T.; Evans, M.K.;
Zonderman, A.B. Serum Uric Acid and Its Association with Longitudinal Cognitive Change among Urban
Adults. J. Alzheimer’s Dis. 2016, 52, 1415–1430. [CrossRef]
43. Alam, A.B.; Wu, A.; Power, M.C.; West, N.A.; Alonso, A. Associations of serum uric acid with incident
dementia and cognitive decline in the ARIC-NCS cohort. J. Neurol. Sci. 2020, 414, 116866. [CrossRef]
[PubMed]
44. Khan, A.A.; Quinn, T.J.; Hewitt, J.; Fan, Y.; Dawson, J. Serum uric acid level and association with cognitive
impairment and dementia: Systematic review and meta-analysis. Age (Omaha) 2016, 38, 1–11. [CrossRef]
[PubMed]
45. Latourte, A.; Bardin, T.; Richette, P. Uric acid and cognitive decline: A double-edge sword? Curr. Opin. Rheumatol.
2018, 30, 183–187. [CrossRef] [PubMed]
46. Afsar, B.; Elsurer, R.; Covic, A.; Johnson, R.J.; Kanbay, M. Relationship between uric acid and subtle cognitive
dysfunction in chronic kidney disease. Am. J. Nephrol. 2011, 34, 49–54. [CrossRef]
47. Perna, L.; Mons, U.; Schöttker, B.; Brenner, H. Association of cognitive function and serum uric acid:
Are cardiovascular diseases a mediator among women? Exp. Gerontol. 2016, 81, 37–41. [CrossRef]
48. Huang, H.Y.; Appel, L.J.; Choi, M.J.; Gelber, A.C.; Charleston, J.; Norkus, E.P.; Miller, E.R., III. The effects of
vitamin C supplementation on serum concentrations of uric acid: Results of a randomized controlled trial.
Arthritis Rheum. 2005, 52, 1843–1847. [CrossRef]
49. Gao, X.; Curhan, G.; Forman, J.P.; Ascherio, A.; Choi, H.K. Vitamin C intake and serum uric acid concentration
in men. J. Rheumatol. 2008, 35, 1853–1858.
50. Berger, L.; Gerson, C.D.; Yü, T.F. The effect of ascorbic acid on uric acid excretion with a commentary on the
renal handling of ascorbic acid. Am. J. Med. 1977, 62, 71–76. [CrossRef]
51. Feigelson, P. The inhibition of xanthine oxidase in vitro by trace amounts of l-ascorbic acid. J. Biol. Chem.
1952, 197, 843–850.
52. Block, G.; Norkus, E.; Hudes, M.; Mandel, S.; Helzlsouer, K. Which plasma antioxidants are most related to
fruit and vegetable consumption? Am. J. Epidemiol. 2001, 154, 1113–1118. [CrossRef]
53. Weber, D.; Davies, M.J.; Grune, T. Determination of protein carbonyls in plasma, cell extracts, tissue
homogenates, isolated proteins: Focus on sample preparation and derivatization conditions. Redox Biol.
2015, 5, 367–380. [CrossRef] [PubMed]
54. Perrotte, M.; Le Page, A.; Fournet, M.; Le Sayec, M.; Rassart, É.; Fulop, T.; Ramassamy, C. Blood-based
redox-signature and their association to the cognitive scores in MCI and Alzheimer’s disease patients.
Free Radic. Biol. Med. 2019, 130, 499–511. [CrossRef]
55. Cristalli, D.O.; Arnal, N.; Marra, F.A.; De Alaniz, M.J.T.; Marra, C.A. Peripheral markers in neurodegenerative
patients and their first-degree relatives. J. Neurol. Sci. 2012, 314, 48–56. [CrossRef] [PubMed]
56. Watfa, G.; Dragonas, C.; Brosche, T.; Dittrich, R.; Sieber, C.C.; Alecu, C.; Benetos, A.; Nzietchueng, R. Study
of telomere length and different markers of oxidative stress in patients with Parkinson’s disease. J. Nutr.
Heal. Aging 2011, 15, 277–281. [CrossRef] [PubMed]
57. Licker, V.; Kövari, E.; Hochstrasser, D.F.; Burkhard, P.R. Proteomics in human Parkinson’s disease research.
J. Proteom. 2009, 73, 10–29. [CrossRef] [PubMed]
Antioxidants 2020, 9, 906 13 of 13
58. Rutishauser, I.H.E.; Bates, C.J.; Paul, A.A.; Black, A.E.; Mandal, A.R.; Patnaikt, B.K. Long-term vitamin status
and dietary intake of healthy elderly subjects. Br. J. Nutr. 1979, 42, 33–42. [CrossRef]
59. Wilson, C.W.M. Clinical pharmacological aspects of ascorbic acid. Ann. N. Y. Acad. Sci. 1975, 258, 355–376.
[CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
